SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...

Arrowhead Pharmaceuticals recently reported dosing the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, an RNAi drug candidate designed to silence both PCSK9 and APOC3 to address atherosclerotic ...

The Web of Science (WoS) has ranked Iran first among Islamic countries in molecular and genetic technologies over the 10 years from 2000 to 2024.

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

Researchers have found that a long-acting injection, given just twice a year alongside standard drugs. Blood pressure is one of the most common health problems worldwide, yet it remains difficult to ...

This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its pipeline.

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Some scientists who argue for deregulation deny outdoor gene editing is possible. But patents and the scientific literature tell a very different story. Report: Claire Robinson ...

Researchers at the University of North Carolina at Chapel Hill have unveiled a platform technology designed to strengthen the potency of RNA interference therapies, a field that has promised targeted ...

International assessments show Iran ranks first in the Islamic world in gene therapy, CRISPR, RNA interference, and cell therapy, securing a leading regional scientific position.

Nicole Steinmetz engineers plant virus nanoparticles into versatile drug-delivery platforms. This work expanded into cancer ...

Scientists at IOCB Prague are uncovering new details of gene transcription. They have identified a previously unknown ...